Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Teva Pharmaceutical Industries rose $0.79 (2.1%) to $38.66 on average volume. Throughout the day, 5,170,152 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4,517,700 shares. The stock ranged in a price between $37.89-$39.00 after having opened the day at $37.89 as compared to the previous trading day's close of $37.87. Other companies within the Drugs industry that increased today were: Insmed ( INSM), up 17.6%, Sucampo Pharmaceuticals Inc. A ( SCMP), up 16.7%, Biocryst Pharmaceuticals ( BCRX), up 11.7% and Neuralstem ( CUR), up 9.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.4 billion and is part of the health care sector. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 1.4% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.

On the negative front, Enzon Pharmaceuticals ( ENZN), down 11.2%, China Pharma ( CPHI), down 9.9%, Merrimack Pharmaceuticals ( MACK), down 7.8% and Cumberland Pharmaceuticals ( CPIX), down 7.3% , were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Allergan 'Very Attractive' After Buybacks, Dividend Increase -Cramer Says

CEOs Are Dropping Like Flies

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed